AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Summary Points
- Southeast Asia's aging population and growing middle class create significant opportunities for ASX health stocks.
- Several Australian healthcare companies, including EZZ Life Science and Recce Pharmaceuticals, are expanding their presence in this burgeoning market.
- The demand for quality health goods and services is projected to rise, fostering trade and investment opportunities across the region.
Southeast Asia is emerging as a prime business opportunity for ASX health stocks, driven by an aging population, a burgeoning middle class, and an increasing demand for high-quality health goods and services. According to Australia’s Department of Foreign Affairs and Trade (DFAT), the number of individuals aged 65 and older in the region is expected to exceed 100 million by 2040. This demographic shift indicates a growing need for enhanced medical products and services.
As Southeast Asia becomes more prosperous, the demand for superior health offerings is anticipated to rise, leading to more trade and investment opportunities for Australian and Southeast Asian businesses in the healthcare sector.
Key ASX Health Companies Targeting Southeast Asia
Several Australian healthcare companies are recognizing the potential of Southeast Asia. Notable players include:
EZZ Life Science (ASX:EZZ)
EZZ Life Science has made strides in Vietnam by launching EAORON branded products. With a rapidly expanding middle class, Vietnam represents a lucrative market for EZZ’s offerings. The company has more than 50 EZZ-branded products and distribution rights to EAORON skincare products in various countries, including Australia and New Zealand. EZZ’s chairman, Glenn Cross, highlighted that 16 EAORON products are now registered in Vietnam, including the popular EAORON Hyaluronic Acid Glutathione Essence Face Mask. The recent partnership with the Guardian retail chain and sponsorship of the Australian Open further positions EZZ to connect with Southeast Asian consumers.
Recce Pharmaceuticals (ASX:RCE)
Recce Pharmaceuticals is addressing the global health challenge of antibiotic-resistant superbugs with its innovative synthetic anti-infectives. The company has partnered with PT Etana Biotechnologies Indonesia to research and commercialize a first-in-class therapeutic for the Southeast Asian market. RCE’s CEO, James Graham, noted that this collaboration underscores a shared commitment to public health between the Australian and Indonesian governments. With a high prevalence of diabetes in Indonesia, RCE is preparing for a Phase 3 clinical trial focused on diabetic foot infections, responding to significant unmet medical needs.
Orthocell (ASX:OCC)
Orthocell is a regenerative medicine company developing products for various bone and soft tissue injuries. After gaining approval in the U.S., EU, and Australia, Orthocell is anticipating regulatory approval for its Striate+ product in Singapore within six to twelve months. Striate+ is designed to enhance dental guided bone and tissue regeneration procedures. The company is also working to expand its Remplir technology, a collagen wrap for peripheral nerve repair, into new markets, including Thailand.
Osteopore (ASX:OSX)
Osteopore specializes in 3D-printed bioresorbable implants for neurosurgical and orthopedic applications. Earlier this year, the company secured market approval for its orthopaedic products in Singapore and Vietnam, positioning itself for complex bone reconstruction procedures. CEO Dr. Lim Yujing emphasized that Southeast Asia represents a critical market for Osteopore, with notable opportunities in Vietnam, Singapore, and the Philippines, while acknowledging the need for a tailored approach in each country.
Jatcorp (ASX:JAT)
Jatcorp is focusing on the health and wellness consumer goods sector. The company’s CEO, Sunny Liang, noted the significant potential in Southeast Asia, building on its successes in China. Jatcorp is distributing products in Singapore and Vietnam and recently participated in the VitaFoods Expo in Bangkok, highlighting the increasing interest in its lactoferrin-enriched functional food products. The company is committed to driving innovation and expanding its reach in this dynamic region.
With an aging population and rising disposable incomes, Southeast Asia presents a robust market for ASX health stocks. Companies like EZZ Life Science, Recce Pharmaceuticals, Orthocell, Osteopore, and Jatcorp are poised to take advantage of the growing demand for quality health products and services, creating exciting trade and investment opportunities across the region.
